Thyroid cancer is often considered a malignancy that works well. However, clinically, 5% of locally advanced patients still face the dilemma of inability to operate, wide range of surgery, large trauma, and high local recurrence rate, which is the main cause of death of thyroid cancer patients.
On December 13, the surging news reporter learned from the Affiliated Cancer Hospital of Fudan University that in order to enable more patients with locally advanced thyroid cancer to have the opportunity to completely remove the tumor by surgery, Wang Yu, director of the head and neck surgery department of the hospital, led a team to carry out a clinical study on the new adjuvant treatment of the targeted drug "anlotinib" in locally advanced thyroid cancer.
The clinical study included 13 patients with locally advanced thyroid cancer that could not be cured by surgery, and each patient received an average of 3.5 cycles of adjuvant neotherapy for allotinib to evaluate the possibility of surgery. Nine of these patients achieved the desired results and eventually underwent radical resection.
Wang Yu said that the incidence of thyroid cancer has shown a significant upward trend in recent years, and the incidence of thyroid cancer in China has increased by nearly 3 times in the past 30 years. In Shanghai, the incidence of thyroid cancer has become the second highest incidence of cancer in women, and at present, multidisciplinary comprehensive treatment based on surgery is the main method of curing thyroid cancer, which can obtain very good curative effect.
"The above results of this study are the first successful demonstration of the effectiveness of allotinib in the neoadjuvant treatment of thyroid cancer, which has won the opportunity for surgery for advanced patients." At the same time, the neoadjuvant treatment model is expected to become a new option for local advanced thyroid cancer treatment. Wang Yu said.
The hospital revealed that this research result has successfully filled the "gap" in the treatment of locally advanced thyroid cancer for the first time in the world, and the relevant papers have been published online in the authoritative journal "Thyroid" in the field of international thyroid diseases.
![3＋2！ A number of research achievements of the University of Science and Technology of China were selected as the highlights of scientific and technological innovation of the Chinese Academy of Sciences in 2021[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)